Tyra Biosciences, Inc.
A biotechnology company developing targeted therapeutics to overcome tumor resistance and improve outcomes for cancer patients. The company is using a proprietary platform to develop a pipeline of selective inhibitors of fibroblast growth factor receptors (FGFRs). Its lead product candidate is TYRA-300, focused on bladder cancer and metastatic urothelial carcinoma. The company is based in Delaware.
Overview
Overview | |
|---|---|
Country | United States |
State | California |
Employees | 49 |
Founded | 2018 |
Financials | |
|---|---|
Market Capitalization | 1.04B |
Revenue | |
Operating Income | -87.93M |
Operating Margin | |
Net Income | -75.45M |
Ranking
Operating Income
Operating Income Ranking | |
|---|---|
All | 4726 / 5373 |
Sector : Healthcare | 853 / 1144 |
Industry : Biotechnology | 424 / 645 |
Market Capitalization
Market Capitalization Ranking | |
|---|---|
All | 2436 / 5565 |
Sector : Healthcare | 315 / 1182 |
Industry : Biotechnology | 127 / 670 |
Net Income
Net Income Ranking | |
|---|---|
All | 4587 / 5436 |
Sector : Healthcare | 825 / 1164 |
Industry : Biotechnology | 411 / 659 |
Employees
Employees Ranking | |
|---|---|
All | 4446 / 5330 |
Sector : Healthcare | 808 / 1174 |
Industry : Biotechnology | 376 / 667 |